Biodexa Pharmaceuticals Plc
BDRXRating Trend
Earnings History
Next report: Apr 23, 2027| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 11, 2026 | $0.00 | — | — | — |
| Mar 27, 2026 | $-0.00 | $-0.05 | — | — |
| Sep 12, 2025 | $-0.01 | $-0.16 | — | — |
| Apr 11, 2025 | $-0.26 | $-0.25 | — | $16.6K |
| Sep 26, 2024 | $-13.40 | $-8.94 | — | $16.6K |
| Jun 13, 2024 | $-141.79 | $-141.68 | $106.0K | $105.8K |
| Sep 15, 2023 | $-140425.00 | — | $377.4K | — |
| Apr 28, 2023 | $-3347825.00 | — | $283.9K | — |
News
October 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and database lock Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has enrolled 100 patients in its registration…
Today's interview with Stephen Stamp, CEO of Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which the only current remedy is surgical removal of the colon and/or rectum. Key takeaways: eRapa is an oral drug candidate designed to reduce or eliminate the need for surgical treatments; a Phase 3 registrational trial, running at 29 U.S. and EU centers, is more than 50 percent enr…
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,2…
September 11, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, today announces its unaudited interim results for the six months ended June 30, 2026 which will also be made available on the Company's website at https://biodexapharma.com/ . OPERATI…
August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has exceeded the half-way point in the recruitment of subjects in its registrational Phase 3 trial of eRapa in…